Results 141 to 150 of about 82,478 (265)

Glycosylated dendrimer nanoamplifiers hijack DNA damage‐immune crosstalk for enhanced dual‐track therapy of orthotopic glioblastoma

BMEMat, EarlyView.
A glycosylated dendrimer nanoamplifier hijacks DNA damage‐immune crosstalk for enhanced radio‐immunotherapy of glioblastoma. The responsive release of demethylcantharidin simultaneously blocks repair‐mediated resistance by inhibiting DNA repair and overcomes adaptive immune resistance.
Cong Song, Binghan Liu, Junjie Liu, Ce Li, Wenqing Man, Xurui Sun, Chang Yuan, Yanjun Wang, Hong Pan, Shuanglian Wang, Zhiming Zheng   +10 more
wiley   +1 more source

Orchestrating the metastatic symphony: the role of extracellular vesicles in the epithelial–mesenchymal transition and pulmonary niche formation of breast cancer

Biological Reviews, EarlyView.
ABSTRACT The complexity of breast cancer (BC) lung metastasis lies in the capacity of tumour cells to interact efficiently with distant organs to promote colonisation, a process that involves the sophisticated coordination of inherent cellular plasticity and the remodelling of the distant microenvironment.
Jian Lu, Reza Shirazi Nia, Junjie Sun, Chrysa Filippopoulou, Daniel De Vega, Pengtao Hu, Heng Liang, Hang Yao, Chaoyue Pan, Xiaoyan Wu, Xidong Gu, Xiaohong Xie, Georgios Giamas   +12 more
wiley   +1 more source

Living Microbial Drugs

Chemistry – A European Journal, EarlyView.
The introduction outlines the review scope. Microbial cell factories as living drugs cover host–gut microbiota, bacteria, yeast, and other microbial systems, with comparative host advantages. Engineering strategies include synthetic circuits, quorum sensing, and memory.
Cemile Elif Özçelik, Nazlıcan Tunç, Senem Şen, Urartu Özgür Şafak Şeker   +3 more
wiley   +1 more source

From Inflammatory Bowel Disease to Cancer: Gut Microbiota–Immune Microenvironment Crosstalk and Natural Product‐Based Therapeutic Opportunities

Cancer Nexus, EarlyView.
ABSTRACT Inflammatory bowel disease (IBD), primarily Crohn's disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract and an important risk factor for IBD‐associated cancer. Increasing evidence suggests that gut microbiota dysbiosis, epithelial barrier dysfunction, and immune microenvironment remodeling
Xue Zhang, Chongchong Gao, Rui Jiang, Zijian Wu, Jian Bai   +4 more
wiley   +1 more source

Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients

Clinical Pharmacology &Therapeutics, EarlyView.
ISB 2001 is a trispecific antibody that binds to two tumor‐associated antigens (TAA), CD38 and BCMA, and crosslinks to CD3 on T cells resulting in T cell‐mediated cytotoxicity of tumor cells expressing these TAAs. ISB 2001 is currently being tested in relapsed and/or refractory multiple myeloma (RRMM) patients in the first‐in‐human (FIH) TRIgnite‐1 ...
Vinu Chandralayam Ayyappa Menon, Tomomi Matsuura, Beata Holkova, Girish S. Gudi, Adam Drake, Maria Pihlgren, Piet H. van der Graaf, Sunitha GN, Andrew Garton, Mario Perro, Cyril Konto, Lida Pacaud   +11 more
wiley   +1 more source

Cytokine-induced PD-L1 and PD-L2 expression is preserved but reverse signalling is altered in rheumatoid arthritis fibroblast-like synoviocytes

Arthritis Research & Therapy
Background Dysfunctional programmed cell death-1 (PD1) signalling may contribute to persistent immune activation in rheumatoid arthritis (RA). However, co-inhibitory molecule interactions between T cells and fibroblast-like synoviocytes (FLS) remain ...
Tilia Selldén, Anna-Karin Hultgård Ekwall, Georgios Chatziagorou, Anna-Carin Lundell, Anna Rudin   +4 more
doaj   +1 more source

Spotlight on nuclear PD-L1 in ovarian cancer chemoresistance: hidden but mighty

Frontiers in Immunology
IntroductionOvarian cancer (OVCA) has a five-year survival rate of approximately 45%, with little improvement over recent decades. Although anti-PD-L1 therapies have shown substantial efficacy in other solid tumors, their effectiveness in OVCA has been ...
Meshach Asare-Werehene, Meshach Asare-Werehene, Meshach Asare-Werehene, Meshach Asare-Werehene, Arvin Zaker, Shivanshi Tripathi, Laudine Communal, Euridice Carmona, Anne-Marie Mes-Masson, Benjamin K. Tsang, Benjamin K. Tsang, Benjamin K. Tsang, Arvind Mer, Arvind Mer, Arvind Mer   +14 more
doaj   +1 more source

Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications

Barrier Immunity, EarlyView.
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu, Shih‐Yu Hung, Fatma Saaoud, Ying Shao, Yifan Lu, Juanjuan Liu, Bo Yuan, Haiyan Xiang, Hong Wang, Xiaofeng Yang   +9 more
wiley   +1 more source

N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1

Background The PD-L1/PD-1 pathway is crucial for immune regulation and has become a target in cancer immunotherapy. However, in order to improve patient selection for immune checkpoint blockade (ICB) therapies, better selection criteria are needed.
Moshe Elkabets, Eman Gharra, Muhammad Abu-Ahmad, Daniela Gologan, Yoav Nuta, Bar Kaufman, Tomer Cooks, Baisali Bhattacharya, Tal Manko, Tsipi Meshel, Olga Radinsky, Angel Porgador, Nofar Erlichman, Adit Ben-Baruch   +13 more
core   +1 more source

Brain–Computer Interfaces: The Dawn of a New Era in Disease Treatment

Exploration, EarlyView.
This study investigates the potential of brain–computer interface (BCI) technology in treating neuropsychiatric disorders, such as movement and communication barriers. Our review examines the history, signal paradigms, and diverse applications of BCI while also discussing ongoing research into novel materials and emerging technologies that offer ...
Yuqi Feng, Wangzheqi Zhang, Jun Chen, Huang Wu, Lei Wu, Yanhao Qiu, Xiaoming Deng, Chenglong Zhu, Yisheng Chen, Zhijie Zhao, Changli Wang, Xiaomin Zhang   +11 more
wiley   +1 more source